CSO Francis Plat to retire Dec 31; company details etripamil commercial plan with NDA in mid-2023

Milestone Pharmaceuticals Inc.

CSO Francis Plat retires Dec 31, 2022; consulting agreement at $15k/month (Stage 1) or $300/hr (Stages 2/3).
RAPID Phase 3 data: 64% conversion at 30 min (etripamil) vs 31% placebo; median time 17 min vs 54 min.
NDA submission for etripamil in PSVT expected mid-2023; development in AFib-RVR also underway.
Initial target market 600,000–900,000 patients; net price estimate $500–$1,000/Rx; cardiologists report 53% adoption.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Francis Plat

Chief Scientific Officer

MIST · Milestone Pharmaceuticals Inc.

Effective: 2022-12-31
Filed: December 6, 2022, 6:59 PM ET

Mr. Oliveto, the Company’s Chief Executive Officer, announced Mr. Francis Plat’s intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Francis Plat departed as Chief Scientific Officer at Milestone Pharmaceuticals Inc..

Action: retire
Role: Chief Scientific Officer

Exact text from the filing

Mr. Oliveto, the Company’s Chief Executive Officer, announced Mr. Francis Plat’s intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.

View on SEC.gov

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-124907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.